

# Apoptosis Regulator BAX - Drugs In Development, 2021

<https://marketpublishers.com/r/A64CD54BBAA9EN.html>

Date: June 2021

Pages: 46

Price: US\$ 3,500.00 (Single User License)

ID: A64CD54BBAA9EN

## Abstracts

Apoptosis Regulator BAX - Drugs In Development, 2021

### SUMMARY

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Apoptosis regulator BAX or bcl-2-like protein 4 is a protein is encoded by the BAX gene. It accelerates programmed cell death by antagonizing the apoptosis repressor BCL2. It promotes activation of CASP3, and thereby apoptosis. It undergoes a conformation change that causes translocation to the mitochondrion membrane, leading to the release of cytochrome c that then triggers apoptosis under stress conditions.

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) pipeline Target constitutes close to 8 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 1 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System and Ophthalmology which include indications Lung Cancer, Acute Ischemic Stroke, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Amyotrophic Lateral Sclerosis, Hepatocellular Carcinoma, Melanoma, Myocardial Infarction and Parkinson's Disease.

The latest report Apoptosis Regulator BAX - Drugs In Development, 2021, outlays comprehensive information on the Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule

type. It also reviews key players involved in Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX)

The report reviews Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics and enlists all their major and minor projects

The report assesses Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Overview

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Companies

Involved in Therapeutics Development

Genervon Biopharmaceuticals LLC

Lytix Biopharma AS

PHD Biosciences

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Drug Profiles

CYD-211 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-6 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LTX-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Apoptosis Regulator BAX for Lung Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## Small Molecule to Activate BAX for Acute Myelocytic Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## Small Molecule to Inhibit BAX for Myocardial Infarction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## Small Molecules to Inhibit BAX for Ophthalmology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## SMBA-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Dormant Products

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Product

Development Milestones

Featured News & Press Releases

Feb 26, 2018: Genervon Presents Innovative CNS Drug Candidate at 2018 BIO CEO & Investor Conference

Dec 08, 2017: GM604 Is a Multi-Target Regulator That Provides a Novel Treatment Strategy for ALS

Apr 06, 2017: Lytix Biopharma presents poster on LTX-401 at AACR in Washington April 2017

Mar 23, 2017: Confidential Data from Genervon ALS Phase 2A Clinical Trial Were Released and Published

Jan 10, 2017: Genervon Releases ALS, PD and AD Disease Associated Gene Lists Modulated by GM6 and Encourages Researchers to Explore New Discoveries beyond Single Target Drug Development Paradigm

Dec 27, 2016: ALS and Alzheimer's disease bioinformatics reports confirm GM6's role as regulator of disease-relevant pathways

Sep 21, 2016: Lytix Biopharma develops second generation oncolytic molecules for deep seated tumors

Jun 06, 2016: GENERVON GM604 received EUs orphan drug designation to treat ALS

May 23, 2016: ALS Patients from Around the World Responding Well to Genervons GM604

May 03, 2016: GM604 to Be Granted "Orphan Drug" Status in Europe

Sep 22, 2015: Genervon GM604 Reduced TDP-43 Protein Aggregates and Slowed Down ALS Progression

Jun 29, 2015: Genervon Filed Patent for Using GM604 Modulations of ALS Disease Biomarkers Showing Homeostasis, Leading to Prognosis and Therapeutic Treatment for ALS Disease

Apr 17, 2015: Amyotrophic Lateral Sclerosis Statement; FDA

Jan 08, 2015: Genervon Announces ALS Compassionate Use Results

Oct 19, 2014: Genervon Announces ALS and PD Phase 2a Trial Results

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2021  
Number of Products under Development by Therapy Areas, 2021  
Number of Products under Development by Indication, 2021  
Number of Products under Development by Companies, 2021  
Products under Development by Companies, 2021  
Number of Products under Investigation by Universities/Institutes, 2021  
Products under Investigation by Universities/Institutes, 2021  
Number of Products by Stage and Mechanism of Actions, 2021  
Number of Products by Stage and Route of Administration, 2021  
Number of Products by Stage and Molecule Type, 2021  
Pipeline by Genervon Biopharmaceuticals LLC, 2021  
Pipeline by Lytix Biopharma AS, 2021  
Pipeline by PHD Biosciences, 2021  
Dormant Projects, 2021

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021



## I would like to order

Product name: Apoptosis Regulator BAX - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/A64CD54BBAA9EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A64CD54BBAA9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970